C Diff Drug Development

C Diff Drug Development

1027 bookmarks
Custom sorting
C. difficile Infection Therapeutic Drug Market Size and Market Drivers Analysis | Growth Rate and Forecast till 2030 | with 131 Pages
C. difficile Infection Therapeutic Drug Market Size and Market Drivers Analysis | Growth Rate and Forecast till 2030 | with 131 Pages
Recent research on the "C. difficile Infection Therapeutic Drug Market" offers a thorough analysis of market growth prospects as well as current kinds [Metronidazole, Vancomycin, Fidaxomicin, Bezlotoxumab] and
·news.google.com·
C. difficile Infection Therapeutic Drug Market Size and Market Drivers Analysis | Growth Rate and Forecast till 2030 | with 131 Pages
The microbial-derived bile acid lithocholate and its epimers inhibit Clostridioides difficile growth and pathogenicity while sparing members of the gut microbiota - PubMed
The microbial-derived bile acid lithocholate and its epimers inhibit Clostridioides difficile growth and pathogenicity while sparing members of the gut microbiota - PubMed
Clostridioides difficile is a Gram-positive, spore-forming anaerobe that causes clinical diseases ranging from diarrhea and pseudomembranous colitis to toxic megacolon and death. C. difficile infection (CDI) is associated with antibiotic usage, which disrupts the indigenous gut microbi …
·pubmed.ncbi.nlm.nih.gov·
The microbial-derived bile acid lithocholate and its epimers inhibit Clostridioides difficile growth and pathogenicity while sparing members of the gut microbiota - PubMed
Bacillus velezensis DSM 33864 reduces Clostridioides difficile colonization without disturbing commensal gut microbiota composition - PubMed
Bacillus velezensis DSM 33864 reduces Clostridioides difficile colonization without disturbing commensal gut microbiota composition - PubMed
Up to 25% of the US population harbor Clostridioides difficile in the gut. Following antibiotic disruption of the gut microbiota, C. difficile can act as an opportunistic pathogen and induce potentially lethal infections. Consequently, reducing the colonization of C. difficile in at-risk populations …
·pubmed.ncbi.nlm.nih.gov·
Bacillus velezensis DSM 33864 reduces Clostridioides difficile colonization without disturbing commensal gut microbiota composition - PubMed
The long and sinuous road to phage-based therapy of Clostridioides difficile infections - PubMed
The long and sinuous road to phage-based therapy of Clostridioides difficile infections - PubMed
With the antibiotic crisis and the rise in antimicrobial resistance worldwide, new therapeutic alternatives are urgently needed. Phage therapy represents one of the most promising alternatives but for some pathogens, such as Clostridioides difficile, important challenges are being faced. The …
·pubmed.ncbi.nlm.nih.gov·
The long and sinuous road to phage-based therapy of Clostridioides difficile infections - PubMed
Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of Clostridioides difficile - PubMed
Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of Clostridioides difficile - PubMed
TcdA and TcdB are known as the major virulence attributes of Clostridioides difficile. Hence, neutralizing the TcdA and TcdB activities can be considered as an efficient therapeutic approach against C. difficile infection (CDI). In this work, we utilized phage display technique to sele …
·pubmed.ncbi.nlm.nih.gov·
Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of Clostridioides difficile - PubMed
Design of 8-mer peptides that block Clostridioides difficile toxin A in intestinal cells - PubMed
Design of 8-mer peptides that block Clostridioides difficile toxin A in intestinal cells - PubMed
Infections by Clostridioides difficile, a bacterium that targets the large intestine (colon), impact a large number of people worldwide. Bacterial colonization is mediated by two exotoxins: toxins A and B. Short peptides that can be delivered to the gut and inhibit the biocatalytic activity of these …
·pubmed.ncbi.nlm.nih.gov·
Design of 8-mer peptides that block Clostridioides difficile toxin A in intestinal cells - PubMed
Design, Synthesis and Biological Evaluation of Novel PEG-Rakicidin B1 Hybrid as Clostridium difficile (CD) Targeted Anti-Bacterial Agent - PubMed
Design, Synthesis and Biological Evaluation of Novel PEG-Rakicidin B1 Hybrid as Clostridium difficile (CD) Targeted Anti-Bacterial Agent - PubMed
Rakicidin B1 was isolated and purified from the culture broth of a marine Streptomyces sp. as a potent anti-cancer agent, and lately the compound and its derivatives have firstly been found to possess anti-Clostridium difficile (CD) activity but with high cytotoxicity. Herein, followin …
·pubmed.ncbi.nlm.nih.gov·
Design, Synthesis and Biological Evaluation of Novel PEG-Rakicidin B1 Hybrid as Clostridium difficile (CD) Targeted Anti-Bacterial Agent - PubMed
Returning to Nature for the Next Generation of Antimicrobial Therapeutics - PubMed
Returning to Nature for the Next Generation of Antimicrobial Therapeutics - PubMed
Antibiotics found in and inspired by nature are life-saving cures for bacterial infections and have enabled modern medicine. However, the rise in resistance necessitates the discovery and development of novel antibiotics and alternative treatment strategies to prevent the return to a pre-antibiotic …
·pubmed.ncbi.nlm.nih.gov·
Returning to Nature for the Next Generation of Antimicrobial Therapeutics - PubMed
Promising Results with a C Diff Vaccine
Promising Results with a C Diff Vaccine
Vaccination is one approach for preventing Clostridioides difficile infection (CDI). A previous study of a three-dose C. difficile vaccine using
·news.google.com·
Promising Results with a C Diff Vaccine
Synthetic microbial consortia for the treatment of Clostridioides difficile infection in mice model - PubMed
Synthetic microbial consortia for the treatment of Clostridioides difficile infection in mice model - PubMed
Clostridioides difficile infection (CDI) as of recent has become a great concern to the impact on human health due to its high hazardous risk and rate of recurrence. Live bacterial therapeutics is a promising method to treat or prevent CDI. Here, a synthetic microbial consortia (SMC) B10 was constru …
·pubmed.ncbi.nlm.nih.gov·
Synthetic microbial consortia for the treatment of Clostridioides difficile infection in mice model - PubMed
Investigational C diff Antibody Takes Novel Mechanism of Action Approach
Investigational C diff Antibody Takes Novel Mechanism of Action Approach
Lumen Bioscience's C diff therapy, LMN-201, combines four therapeutic proteins that act synergistically to neutralize both the C difficile bacterium and the toxin that causes its virulence directly in the patient’s gastrointestinal tract.
·news.google.com·
Investigational C diff Antibody Takes Novel Mechanism of Action Approach
Tech-Heavy Drug Discovery Yields Deep Pipeline
Tech-Heavy Drug Discovery Yields Deep Pipeline
Recursion Cofounder and CEO, Chris Gibson, Ph.D. is creating a map of human biology comparable to Google’s ongoing effort to map every street on the planet. He shared why that's so important, and how it's informing Recursion's rapid drig discovery efforts.
·news.google.com·
Tech-Heavy Drug Discovery Yields Deep Pipeline
C. difficile Infection Therapeutic Drug Professional Market 2031 Key Insights and Leading Players Astellas Pharma, Actelion Pharmaceuticals Ltd, Sanofi S.A., Pfizer Inc., Merck & Co., Inc., etc - University City Review
C. difficile Infection Therapeutic Drug Professional Market 2031 Key Insights and Leading Players Astellas Pharma, Actelion Pharmaceuticals Ltd, Sanofi S.A., Pfizer Inc., Merck & Co., Inc., etc - University City Review
The new research, "C. difficile Infection Therapeutic Drug Professional Industry 2023" provides an i
·news.google.com·
C. difficile Infection Therapeutic Drug Professional Market 2031 Key Insights and Leading Players Astellas Pharma, Actelion Pharmaceuticals Ltd, Sanofi S.A., Pfizer Inc., Merck & Co., Inc., etc - University City Review
Global Live Biotherapeutic Products and Microbiome CDMO Market Expected to Reach $159.1 Million by 2029, Driven by Rising Demand for Novel Treatments and Therapies
Global Live Biotherapeutic Products and Microbiome CDMO Market Expected to Reach $159.1 Million by 2029, Driven by Rising Demand for Novel Treatments and Therapies
/PRNewswire/ -- The "Global Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Industry Trends Analysis Report By Application (C.difficile,...
·news.google.com·
Global Live Biotherapeutic Products and Microbiome CDMO Market Expected to Reach $159.1 Million by 2029, Driven by Rising Demand for Novel Treatments and Therapies
Mirikizumab Bests Placebo in Treating Patients With Ulcerative Colitis
Mirikizumab Bests Placebo in Treating Patients With Ulcerative Colitis
There were higher percentages of patients treated with mirikizumab that had clinical remission at week 12 of the induction trial compared to the placebo group. This was also true at week 40 of the maintenance trial.
·news.google.com·
Mirikizumab Bests Placebo in Treating Patients With Ulcerative Colitis
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
Probiotics and yogurt could help restore the balance of the gut microbiota.Regular consumption of yogurt was related to a greater abundance of Streptococcus and lower abundance of Odoribacter among healthy adults (no associations found for probiotics):https://t.co/rT7HFOAsW8— GutMicrobiota Health (@GMFHx) July 24, 2023
·twitter.com·
GutMicrobiota Health on Twitter
Glycosides as Potential Medicinal Components for Ulcerative Colitis: A Review
Glycosides as Potential Medicinal Components for Ulcerative Colitis: A Review
Ulcerative colitis (UC) is a chronic, non-specific disease of unknown etiology. The disease develops mainly in the rectum or colon, and the main clinical symptoms include abdominal pain, diarrhea, and purulent bloody stools, with a wide variation in severity. The specific causative factors and pathogenesis of the disease are not yet clear, but most scholars believe that the disease is caused by the interaction of genetic, environmental, infectious, immune, and intestinal flora factors. As for the treatment of UC, medications are commonly used in clinical practice, mainly including aminosalicylates, glucocorticoids, and immunosuppressive drugs. However, due to the many complications associated with conventional drug therapy and the tendency for UC to recur, there is an urgent need to discover new, safer, and more effective drugs. Natural compounds with biodiversity and chemical structure diversity from medicinal plants are the most reliable source for the development of new drug precursors. Evidence suggests that glycosides may reduce the development and progression of UC by modulating anti-inflammatory responses, inhibiting oxidative stress, suppressing abnormal immune responses, and regulating signal transduction. In this manuscript, we provide a review of the epidemiology of UC and the available drugs for disease prevention and treatment. In addition, we demonstrate the protective or therapeutic role of glycosides in UC and describe the possible mechanisms of action to provide a theoretical basis for preclinical studies in drug development.
·t.co·
Glycosides as Potential Medicinal Components for Ulcerative Colitis: A Review
The inhibitory effects of live and UV-killed Akkermansia muciniphila and its derivatives on cytotoxicity and inflammatory response induced by Clostridioides difficile RT001 in vitro - PubMed
The inhibitory effects of live and UV-killed Akkermansia muciniphila and its derivatives on cytotoxicity and inflammatory response induced by Clostridioides difficile RT001 in vitro - PubMed
Clostridioides difficile infection (CDI) is the leading cause of healthcare-acquired infections worldwide. Probiotics are widely recommended to prevent CDI and its recurrences. Akkermansia muciniphila, as a therapeutic symbiont colonizing the intestinal mucosal layer, is considered to be a promising …
·pubmed.ncbi.nlm.nih.gov·
The inhibitory effects of live and UV-killed Akkermansia muciniphila and its derivatives on cytotoxicity and inflammatory response induced by Clostridioides difficile RT001 in vitro - PubMed
Recursion: Shaking Up The Landscape With Data-Driven Blueprint
Recursion: Shaking Up The Landscape With Data-Driven Blueprint
Recursion uses a data-driven approach to drug discovery, launching four clinical trials in 2021 and planning a fifth in oncology. Click here to read more.
·seekingalpha.com·
Recursion: Shaking Up The Landscape With Data-Driven Blueprint
Investigational C diff Antibody Takes Novel Mechanism of Action Approach
Investigational C diff Antibody Takes Novel Mechanism of Action Approach
Lumen Bioscience's C diff therapy, LMN-201, combines four therapeutic proteins that act synergistically to neutralize both the C difficile bacterium and the toxin that causes its virulence directly in the patient’s gastrointestinal tract.
·contagionlive.com·
Investigational C diff Antibody Takes Novel Mechanism of Action Approach